Neurological complications frequently affect chronic kidney disease patients. They are important causes of morbidity and mortality. We present a review of neurological complications affecting hemodialysis patients, focusing on classical and new aspects. Neurological complications can be classified as central or peripheral, but they also include other conditions such as muscle and autonomic disorders. Neurological complications in hemodialysis patients are often underdiagnosed and undertreated. Dialysis treatment can modify the clinical pattern and the course of neurological complications, but it may also directly induce some specific, dialysis-related complications. A strict collaboration between nephrologists, neurologists and other specialists can potentially improve prevention and management of these disorders and improve quality of life for hemodialysis patients.
CKD; others may be secondary to dialysis treatment itself. Neurological manifestations may affect both the central and peripheral nervous systems (Tabs. I and II). Uremic encephalopathy, atherosclerosis, neuropathy and myopathy are the most severe clinical manifestations of uremia (1, 2) . In this article, we focus our attention on neurological complications affecting hemodialysis patients. We reviewed the current literature on neurological complications reported in hemodialysis patients. We describe the main clinical manifestations, diagnostic and therapeutic approaches, impact on patients' quality of life and recent insights. We considered dialysis-induced and dialysis-modified neurological complications (Tab. II), which were classified in central disturbances, peripheral disturbances and other disturbances or "miscellanea," discussed in dedicated paragraphs. This approach derives from the consideration that dialysis treatment can modify the clinical pattern and the course of neurological complications, but it may also induce some specific, dialysis-related complications. Compared with those for the early times of dialysis, the incidence rates of uremic encephalopathy, neuropathy and myopathy have decreased, but in many patients these conditions do not improve significantly in response to dialysis therapy, with the exception of some improvement of uremic encephalopathy and chronic pruritus. Some neurological disturbances are directly induced by dialysis, such as dialysis dementia and dialysis disequilibrium syndrome. Indirectly, dialysis may be associated with worsening atherosclerosis and with the risk of hemorrhagic stroke (Tab. II).
IntroductIon
Neurological complications frequently affect chronic kidney disease (CKD) patients, and they are important causes of morbidity and mortality (1) . They involve both predialysis and dialysis patients. Some of them are primarily related to 
Dialysis dementia
Dialysis dementia is a subacute, progressive and fatal disease which has occurred in patients chronically dialyzed for periods exceeding 3 years, especially in centers with inappropriately elevated aluminum levels in the water used for dialysis (3, 4) . Typical manifestations are dysarthria, mutism and facial grimacing. The most frequent clinical manifestations are disturbances in speech (90%), in cognition (66%), in movement (75% to 93%) and personality changes. When not recognized, it may progress to death in 6 months. The first symptoms are usually intermittent and characterized by stammering, hesitancy of speech and at times speech arrest. The speech disorder is intensified during and immediately after dialysis. As the disorder progresses, symptoms become more constant, speech more dysarthric and aphasic; dementia and myoclonic jerk usually become apparent at this time. The typical electroencephalographic (EEG) findings show a pathological pattern including bursts of high-voltage slowing in the frontal leads. Patients with dialysis dementia have spongiform changes in the outer 3 cortical layers, with elevated aluminum levels in the cerebral cortex. Other changes include neuronal loss, accumulation of lipofuscin pigment and neurofibrillary degeneration in the motor cortex and in the red, dentate and olivary nuclei. Dialysis dementia should be differentiated from depression and cerebral atrophy (5, 6) . Diazepam is effective in reducing myoclonus and seizures and improving speech; it becomes less effective in later stages. Increased dialysis time and renal transplantation do not modify the course of the disease, while removal of increased aluminum levels with deferoxamine has been proven an effective treatment, although with relevant side effects.
In the 1980s, a progressively more extensive use of reverse osmosis for dialysis water treatment markedly reduced aluminum levels in the dialysate, with a large reduction in the incidence of dialysis dementia (7). However, it should be kept in mind that in some cases aluminum present in phosphate binders has been found to induce osteomalacia and encephalopathy by accumulation in bone and cerebral tissues (8) . Guidelines recommend avoiding use of aluminum salts as phosphate binders to prevent osteomalacia and encephalopathy (9), but they are still used in some dialysis units in patients with inadequate phosphate control.
Disequilibrium syndrome
Disequilibrium syndrome is defined as a central nervous system disturbance characterized by neurological symptoms due to cerebral edema. Symptoms are generated by an excessively rapid clearing of small-sized molecules, such as urea. A nonspecific increase in cerebral membrane permeability in uremia may permit greater entry of uremic toxins into the brain (10). In particular, there are 2 main theories (11): The first one is the reverse urea effect, suggesting that the shift of urea between brain intracellular space and plasma is not immediate, causing a higher concentration of urea within the brain and leading to cerebral edema. The second theory considers that after hemodialysis, patients have transient paradoxical metabolic acidosis within the central nervous system, displacing sodium and potassium from organic anions, making them osmotically active and leading to cerebral edema (12) . Symptoms vary from mild headache, nausea and muscle cramps to convulsions or delirium; they typically appear 3 to 4 hours after starting dialysis but may manifest themselves 8-24 hours later. The syndrome is usually self-limited, subsiding in hours, but delirium may persist for several days. Risk factors are first hemodialysis treatments, severe uremia in late referral patients, age, preexisting neurological disorders and metabolic acidosis. In severe cases, patients may die from cerebral edema. Treatment of disequilibrium syndrome consists of preventive measures during hemodialysis which include slow, gentle start of hemodialysis, increasing dialysate sodium levels and administration of osmotically active substances (13) . Therefore, it is important to consider this possible diagnosis with unexplained neurological symptoms indicating a central nervous system abnormality.
Central pontine myelinolysis
Defined also as osmotic demyelinization syndrome, central pontine myelinolysis is induced by a rapid correction of hyponatremia causing the extracellular fluid to be relatively hypertonic with secondary damage to the pontine and extrapontine cells of the brain. Initial symptoms are progressive gait disturbance, postural instability, hallucinations and mild cognitive dysfunction (15), progressing to paraparesis or quadriparesis, dysphagia, dysarthria, diplopia and loss of consciousness. A slow correction of hyponatremia permits avoidance of the syndrome. It is suggested that hyponatremia should be corrected at a rate of no more than 8-10 mmol/L of sodium per day to prevent central pontine myelinolysis. Therefore, hemodialysis correction of hyponatremia should also be done carefully, adapting the sodium level of the dialysate to the patient's serum level.
Uremic encephalopathy
Uremic encephalopathy is characterized by dysarthria, instability of gait, asterixis, action tremor, multifocal myoclonus involving muscles first in 1 locus and then in others, from face to proximal limbs, and sensorial clouding. Fluctuation of clinical signs from day to day is characteristic. Asterixis and myoclonus may be so intense that muscles appear to fasciculate; other manifestations include convulsions and uremic twitching as a spontaneous or latent (manifested by a Trousseau sign) carpopedal spasm usually not responsive to injections of calcium and occurring despite metabolic acidosis (16, 17) . It may be related to acute or chronic renal failure, equally affecting males and females (16, 17) . Seizures are more common in acute (40%) than in chronic renal failure (10%). The pathogenesis of uremic encephalopathy has been linked to uremia itself, thiamine deficiency, hypertension, fluid and electrolyte disturbances or drug toxicity. In particular, accumulation of metabolites, hormonal disturbances and an altered balance of excitatory and inhibitory neurotransmitters have been described as risk factors (18) . Renal failure results in accumulation of numerous organic substances which are potential neurotoxins (19) . Increased levels of glycine, organic acids (phenylalanine) and free tryptophan, as well as decreased levels of gamma-aminobutyric acid, may be relevant etiological factors. Transketolase, present in myelinated neurons, is a thiamine-dependent enzyme which maintains myelin sheaths: in uremic patients this enzyme is substantially inhibited (20) . Calcium is an essential neuronal mediator, so that alterations in brain calcium may possibly disrupt cerebral function (21) . EEG abnormalities in uremic encephalopathy are mainly nonspecific. EEG may have diagnostic value especially in serial studies: it generally results in irregular low voltage with slowing of the posterior dominant alpha rhythm and occasional theta bursts with an excess of delta and theta waves and sometimes bilateral spike-wave complexes. Cerebral imaging can provide useful information, while evoked-potential studies have limited value. Brain histological abnormalities include meningeal fibrosis, glial changes, edema, vascular degeneration and focal and diffuse neuronal degeneration. Focal demyelination, small infarcts secondary to hypertension or focal necrosis are also present. Symptoms are usually improved by dialysis or renal transplantation (17, 21) .
Cerebrovascular disorders: atherosclerosis
Cerebrovascular disease is a major cause of morbidity and mortality in CKD patients (22) . Hemodialysis patients are susceptible to develop atherosclerosis and ischemic stroke. Atherosclerosis in CKD patients is generally more diffuse, affecting more distal sites than in the general population, probably due to the combination of traditional and uremiarelated risk factors (23) . Tissue and vascular calcifications secondary to chronic kidney disease-mineral and bone disorder (CKD-MBD) are known to increase arterial stiffness, worsening atherosclerosis symptoms (22, 23) . Finally, CKD patients have a high prevalence of hyperhomocysteinemia, an independent risk factor for atherosclerosis (24) .
Cerebrovascular disorders: hemorrhagic complications
Hemorrhagic stroke may include intracerebral, subarachnoid or subdural hemorrhage. Uremia causes platelet dysfunction and altered platelet-vessel wall interaction resulting in a bleeding tendency (25) . Intradialytic anticoagulation itself may also be an important cause of hemorrhagic complications. Dialytic strategies to reduce bleeding risk include the use of regional or minimal heparinization. Heparin-free dialysis is indicated for patients who are actively bleeding or have recently suffered from a cerebral hemorrhage (26) .
Posterior leukoencephalopathy syndrome
Posterior leukoencephalopathy syndrome is a typical neurological complication of uremia, predominantly affecting the cerebral white matter (27) . The syndrome is characterized by peculiar radiological findings in the posterior brain, which may spread to basal ganglia, brain stem, and cerebellum, inducing headache, nausea, vomiting, visual disturbances, focal neurological deficits and seizures. The lesions of posterior leukoencephalopathy are best visualized with magnetic resonance (MR) imaging. T2-weighted MR images, at the height of symptoms, characteristically show diffuse hyperintensity selectively involving the parieto-occipital white matter. The findings on neuroimaging are characteristic of subcortical edema without infarction. The pathogenesis is still unclear, with several different potential etiological factors: hypertension, drugs, uremia itself and fluid/electrolyte disturbances. Posterior leukoencephalopathy syndrome is often associated with an abrupt increase in blood pressure. Early diagnosis and aggressive treatment of hypertension can make the syndrome completely reversible (27) .
perIpherAl nervous system complIcAtIons

Mononeuropathy
Mononeuropathy may occur because of an increased susceptibility of nerves to injury or as a vascular steal phenomenon after arteriovenous (AV) fistula surgery. Mononeuropathy includes carpal tunnel syndrome, ischemic monomelic neuropathy and anterior ischemic optic neuropathy. Carpal tunnel syndrome is very common among dialysis patients (28) . Entrapment in carpal tunnel may due to dialysis-associated amyloidosis, but it has also been associated with uremic calcinosis and the AV fistula (29) . A correlation was found between the development of clinically evident carpal tunnel syndrome and the side of vascular access, but electrodiagnostic studies did not indicate any significant association between the frequency of carpal tunnel syndrome and AV fistula or its duration (30) . Symptomatic treatment is based on antiinflammatory drugs, steroids or anticonvulsants, while surgical decompression is a more effective, long-lasting therapy. Optimal dialysis can prevent dialysisassociated amyloidosis. Ischemic monomelic neuropathy is another type of mononeuropathy resulting from placement of forearm AV fistulas, which can lead to functional damage and in severe cases to loss of extremity (31, 32) . Its pathogenesis is unclear: multiple risk factors, such as underlying stenotic or occlusive arterial disease, neuropathic diseases or calcifying sclerosis should be considered; accesses from the brachial artery in the absence of collateral vessels, distal axonopathy and diabetic polyneuropathy are other predisposing factors. It is a medical emergency which may require closure of the AV fistula. Alternative strategies are distal revascularization interval legation (DRIL) and proximalization of arterial inflow (PAI), conservative treatments which permit the preservation of the vascular access (33) . Cranial nerve involvement is rare, but several cases of anterior ischemic optic neuropathy have been described. This may be due to interference with the posterior ciliary artery blood supply to the optic nerves, coupled with predisposing factors such as hypertension, hypotension, anemia and atherosclerosis. Start of dialysis, corticosteroid therapy, correction of anemia and adequate blood pressure control may restore vision loss and make the syndrome reversible (34).
Uremic polyneuropathy
Peripheral neuropathy is the most common neurological complication of chronic renal failure (35) , occurring in approximately 60% to 100% of patients with CKD, more commonly in men than women. It is characterized by axonal degeneration with secondary demyelination, and it can affect motor, sensory and cranial nerves. It is typically a distal, symmetric, predominantly axonal, mixed sensitive and motor neuropathy affecting the legs more than the arms. The factors involved in the development of uremic polyneuropathy remain partially unknown: it probably results from removal of thiamine by dialysis treatment (36) . It evolves over several months but may be fulminant. Patients begin to demonstrate clinical signs of peripheral nerve dysfunction when their glomerular filtration rate is less than 12 ml/min. Uremic neuropathy may be subclinical and diagnosed by electrophysiological studies. In mild forms, the most prevalent symptoms are distal paresthesias associated with loss of vibration sense in lower limbs and impairment of ankle reflexes. A more severe form of neuropathy presents an ascending sensory and motor dysfunction. Finally, an acute neuropathy caused by metabolic disturbance related to renal failure may mimic Guillain-Barré syndrome and may be reversible. Adequate removal of dialyzable neurotoxins may increase nerve conduction velocities (37), but hemodialysis itself rarely improves neuropathy. However, patients with mild neuropathy often recover completely. Supplementation with biotin, pyridoxine, cobalamin and thiamine may be an effective treatment; tricyclic antidepressants and anticonvulsants can also be useful as a symptomatic therapy. Lack of improvement of neuropathy in dialysis patients may suggest an alternative diagnosis. It is important to consider the possibility of nonuremic neuropathy in chronic renal failure patients, such as neuropathy associated with graft versus host disease, systemic vasculitis and diabetic polyneuropathy.
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mIscellAneA: AutonomIc system, muscles And others
Hemodialysis headache
Hemodialysis headache is frequent among patients receiving hemodialysis with an incidence of 5% (38) . It usually appears during the third hour of dialysis and lasts less then 4 hours in the majority of patients. It has a moderate intensity; the pain is bilateral and it has been described either as throbbing (38) or nonpulsating (39) . The pathogenesis seems to be related to marked differences of pretreatment and posttreatment urea levels, intradialytic hypotension and changes in magnesium levels. In fact, disequilibrium syndrome may start as a headache. Some patients suffer from headaches before starting chronic hemodialysis treatment, but 20% of patients without previous headache may experience it in association with dialysis. It may disappear following renal transplant, and return in cases of rejection. In the past, dialysis headache was not considered as a distinct diagnostic entity, and hemodialysis itself was considered a nonspecific stress factor (39) . In contrast, in the International Classification of Headache Disorders (40), dialysis headache is defined as a specific entity. Diagnosis in patients on hemodialysis requires at least 3 attacks of acute headache fulfilling the following criteria: headache developing during at least half of hemodialysis sessions, headache resolving within 72 hours after each hemodialysis session and/or ceasing altogether after successful transplantation (40) . Finally, caffeine-withdrawal headache may be considered in patients abusing caffeine, as it is removed by dialysis.
Autonomic dysfunction
Autonomic dysfunction is another important component of uremic neuropathy. Involvement of the parasympathetic system is more frequent than sympathetic system damage. In particular, a defective regulation of the heart rate is more common than deregulation of blood pressure control (41) . It may be reversible with early renal transplantation. Hypotension is a common complication of hemodialysis, and it may be secondary to autonomic neuropathy (42) ; it can result in cerebral hypoperfusion and eventually ischemic stroke. Converse et al (43) suggested that hemodialysis-induced hypovolemia can trigger a vasodepressor reaction, a sudden decrease in sympathetic activity resulting in bradycardia and vasodilation, which would exacerbate the volume-dependent fall in blood pressure. In a group of hemodialysis patients without diabetes or other conditions known to impair autonomic reflexes, they demonstrated that hemodialysis-induced hypotension is not caused by chronic uremic impairment in arterial or cardiopulmonary baroreflexes but rather by acute, paradoxical withdrawal of sympathetic vasoconstrictor drive producing vasodepressor syncope (43) .
Uremic myopathy
Uremic myopathy is characterized by proximal limb weakness, muscles wasting, limited exercise endurance and rapid fatigability (44) . Progression of myopathy is associated with a parallel decline of renal function, with an overall prevalence estimated at 50% in dialysis patients. Possible predisposing factors are represented by the accumulation of uremic toxins, abnormalities in vitamin D metabolism, insulin resistance, carnitine deficiency, malnutrition, anemia and, in particular, abnormalities in mineral and bone metabolism. In the experimental setting, muscle weakness may be rapidly induced by uremic toxins and rapidly reversed, when solutes are removed by dialysis (45) . Fast-twitch muscles are more susceptible to uremic myopathy than slow-twitch muscles (45) . Electromyography and muscle enzymes are generally normal (46) . Prevention and treatment of secondary hyperparathyroidism and anemia, along with dietary corrections, are useful to reduce symptoms (47) . Acute myopathy induced by water and electrolytes disturbances has also been described in uremic patients.
Uremic pruritus
Uremic pruritus can be consider a particular form of neuropathy, affecting about 33% of dialysis patients, with a great impact on their quality of life (48, 49) . Its pathogenesis is multifactorial and not completely understood, involving uremic toxins, dry skin, inadequate control of calcium-phosphorus metabolism and allergy (50, 51) . In particular, 4 hypotheses have been described: dermatological abnormalities, derangement of the immune system resulting in a proinflammatory state, activation of the endogenous opioidergic system and a neuropathic mechanism (52) . In fact, itch neurophysiology mirrors that of pain, supporting the hypothesis that the 2 phenomena are strictly related in hemodialysis patients (53) . According to the neuropathic theory, specific dermal C-receptors are abnormally stimulated, activating spinothalamic neurons sensitive to histamine, which mediate clinical manifestations (54).
Treatment can be challenging. Several effective strategies have been proposed: optimization of dialysis, use of more biocompatible membranes such as polymethylmethacrylate (55) , and treatment of MBDs, as hyperphosphatemia is often associated with chronic pruritus in hemodialysis patients. Finally, symptomatic therapy consists in skin emollients, UVB light, gabapentin (56) and the k-opioid agonist nalfurafine (57) . Regression of severe and refractory uremic pruritus by cyclosporine has also been observed, supporting the hypothesis of immune pathogenesis of uremic pruritus in some cases (58) .
Neurological complications secondary to mineral and bone disorders (MBDs)
Severe hyperparathyroidism, adynamic bone disease and amyloidosis induced by b 2 -microglobulin deposition may determine neurological dysfunctions by different mechanisms. Adynamic bone disease and severe hyperparathyroidism frequently cause pathological fractures, while amyloidosis induced by b 2 -microglobulin deposition may induce severe spondyloarthropathy (29, 30) . Adynamic bone disease is defined as an absolute or partial parathyroid hormone deficit associated with low or absent bone remodeling (59) . It is common among hemodialysis patients (21%). Predisposing factors are total parathyroidectomy, age, diabetes, long-term use of steroids, vitamin D and calcium treatments at high dosage. Patients often present bone fractures, myopathy and vascular calcifications, as low bone turnover facilitates calcium and phosphorus accumulation in vessels. The spine is frequently involved (59) . Neurological consequences of adynamic bone disease may be severe: vertebral collapse can induce secondary neurological disabilities, including tetraplegia. A rare but severe condition determining neurological symptoms is Sagliker syndrome (60) . It has been described in patients affected by severe hyperparathyroidism: severe skull and facial bone changes are associated with alteration of face features as well as neuropsychiatric disease. The most frequent neurological manifestations of this syndrome are headache, polyneuropathy, cranial neuropathy, fatigue and psychiatric disorders (60) . Treatment of neurological complications of CKD-MBD may be highly challenging. We recently observed (61) a case of tetraplegia due to cervical spinal disease secondary to b 2 -microglobulin amyloidosis and adynamic bone disease in a long-term (30-year) dialysis patient (Fig. 1A) . A high risk neurosurgical approach was the only choice, but we observed only temporary improvements of symptoms, followed by recurrence of tetraplegia (Fig. 1B) . Infectious spondylodiscitis can result in deformed vertebral segments and neurological complications. In dialysis patients it is usually caused by bacteria, especially Staphylococci entering into the circulation through the vascular access, but also by Mycobacterium tuberculosis or other microorganisms. Spondylodiscitis is characterized by an inflammation of the base and upper plates of the vertebra as well as the adjoining intervertebral disc. Severe neurological complications can be observed, with sensorimotor defects (paraplegia, paralyses) due to the penetration of abscess or necrotic material into the spinal canal, resulting in spinal cord compression. 
Sleep disorders
Sleep disorders are among the most relevant complications of hemodialysis; they may impair quality of life and contribute to morbidity and mortality (62, 63) . Risks of obstructive and central respiratory events are increased, and excessive daytime sleepiness is often reported in dialysis patients. The most common sleep disorders are insomnia (70%), sleep apnea syndrome (30%-80%) and restless legs syndrome (20%-40%). Insomnia is defined as difficulty in falling asleep, frequent awakening with difficulty in falling asleep again and early morning wakefulness; diagnosis is made when these symptoms are reported at least 3 times a week (63) . Sleep apnea syndrome is characterized by an intermittent interruption of the airflow, which may be associated with arterial hypoxia due to a complete or partial obstruction of the upper airways or a cessation of the respiratory drive from the central respiratory centre. Risk factors are related to lifestyle (smoke, depression or stress) or to comorbidity (uremia itself, anemia and metabolic disorders) (64) . Some authors 
Miscellanea
Useful for
Autonomic nervous system testing Autonomic dysfunction Polysomnography Sleep disorders CT = computed tomography; EEG = electroencephalogram; EMG = electromyography; ENG = electroneurography; MRI = magnetic resonance imaging; PTH = parathyroid hormone.
have suggested a role of somnogenic cytokines in sleep disorders: they cause excessive daytime sleepiness by impairing nocturnal sleep efficiency (62, 65) . Diagnosis is based on clinical interview and polysomnography: a simple screening questionnaire may be used for patients at risk of sleep complaints reserving the neurophysiological examinations for high-risk patients. Treatment of these disturbances can greatly improve clinical outcomes and quality of life.
Restless legs syndrome
Restless legs syndrome occurs in 20%-40% of uremic patients and is characterized by creeping, crawling, prickling and itching sensations deep within the legs. Symptoms worsen with inactivity and in the evening, inducing an urge to move the legs which is often hard to resist, so that patients suffer from severe sleep disturbances (66) . The pathogenesis is still unclear: genetic components and different factors such as anemia or iron deficiency have been proposed as possible causes (67) . In general, dialysis does not substantially improve uremic restless legs syndrome, but cool dialysate fluid can be useful. In some cases, treatment with clonazepam, dopamine agonists, opioids and some anticonvulsants has been successful. Considering the possible role of iron deficiency, high-dose intravenous iron may represent a new experimental treatment.
dIAgnostIc ApproAches to neurologIcAl dIsorders found In hemodIAlysIs pAtIents
Neurological evaluation of hemodialysis patients may be difficult because of the large spectrum and complexity of neurological complications. Early diagnosis is essential for prevention and proper management. The diagnostic approach to dialysis patients affected by neurological disorders must start from a complete clinical examination, focusing on neurological signs and vital parameters. In particular, the diagnostic work-up should define the severity of neurological involvement, recognize if renal failure itself may be a sufficient cause for neurological manifestations and, at the same time, exclude other possible causes of neurological involvement. In this respect, we underline the importance of considering hepatic failure, drug toxicity, infections and immunological disorders, which are potential causes of neurological manifestations. (27) . The use of MRI in combination with new and conventional imaging is very helpful; in particular, diffusion MRI is able to show infarcts earlier than other sequences, while proton MRI spectroscopy is useful for monitoring metabolic alterations (71) .
therApeutIc ApproAches to the mAIn neurologIcAl dIsorders found In hemodIAlysIs pAtIents
Among hemodialysis patients, neurological disorders are important causes of disability. The long-term prognosis depends on the availability of treatment and a prompt management. Therapeutic management of neurological disorders in hemodialysis patients needs a multifactorial approach (1). while vitamin supplementation may improve uremic polyneuropathy. Surgery can be a better option in some cases, as described above for ischemic monomelic neuropathy and in carpal tunnel syndrome. Starting hemodialysis (or renal transplantation) is an effective treatment of uremic encephalopathy. In particular, ad-equate dialysis may improve symptoms related to uremic encephalopathy and uremic polyneuropathy, while renal transplantation may also reverse autonomic dysfunction (72) . Specific dialytic strategies, including slow hemodialysis and the use of high sodium levels in the dialysis fluid, are preventive measures to avoid disequilibrium syndrome. Finally, optimal management of the main complications induced by renal failure itself, such as hyperparathyroidism and anemia, has a crucial role in stabilizing and improving some neurological symptoms. For example, the correction of vitamin D deficiency is able to reduce muscle weakness.
conclusIon
In hemodialysis patients, multiple neurological complications are commonly observed. They are an important cause of mortality and morbidity, but often underdiagnosed and undertreated. Hemodialysis patients need a close follow-up to manage and prevent neurological involvement. Adopting early and adequate treatments or preventative measures should partially resolve symptoms. Despite continuous therapeutic progress, most neurological complications of uremia fail to respond to dialysis treatments; some of them are even induced by hemodialysis itself. All of the available therapeutic measures should be considered, in particular improving and personalizing hemodialysis, and using pharmacological and psychological treatments. Potentially neurotoxic drugs should be dosed accurately, and whenever necessary their serum levels should be monitored to prevent neurological toxicity. At a time of increasingly narrow medical specializations, we should not forget to take a wider look at different clinical arenas. A good historic model of the multidisciplinary approach is Jean-Martin Charcot (73) . When he was already concentrating on the study of neurological disorders, he maintained his life-long interest in the kidney and made major contributions to the study of renal diseases. Similarly, nowadays nephrologists should not forget the importance of neurological knowledge in their medical specialization, as well as the importance of a close collaboration with neurologists, for the benefit of patients with chronic kidney disease. 
